Genetic Predictors of Outcome in HCM Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

98 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-04-22

Study Completion Date

2020-07-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a retrospective review of the data available on patients and their family members with HCM and prospective follow-up of this cohort for clinical outcome and diagnostic studies. Genetic samples are being examined in this cohort to determine whether certain to determine whether certain beta-AR polymorphisms as well as other common genetic polymorphisms are associated with different morphological features, such as LVH in patients with HCM and whether these polymorphisms influence the clinical course and outcome in patients with HCM. For that purpose, we will build a database with clinical information including serial echocardiographic measurements for patients with HCM that have regular follow up and test them for beta-AR polymorphisms as well as other common genetic polymorphisms and other known cardiac-related polymorphisms that can potentially contribute to the morphologic differences seen in patients with HCM.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Genomic Sequencing in Patients With HCM Undergoing Septal Myectomy

NCT03043209

Hypertrophic Cardiomyopathy Genetic Disease Gene Product Sequence Variation

COMPLETED

Study of Clinical and Molecular Manifestations of Genetic Disorders

NCT00001466

Hereditary Diseases

COMPLETED

Genome-wide Epistasis for Cardiovascular Severity in Marfan Study

NCT06257004

Marfan Syndrome FBN1 Mutation

RECRUITING

Genetic Determinants of Congenital Heart Disease Outcomes

NCT01656941

Congenital Heart Disease Hypoplastic Left Heart Syndrome Hypoplastic Right Heart Syndrome +1 more

COMPLETED

Study of Genotype and Phenotype in Patients With Alpha 1-Antitrypsin Deficiency

NCT00005098

Alpha 1-Antitrypsin Deficiency

TERMINATED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a retrospective review of the data available on patients and their family members with HCM and prospective follow-up of this cohort for clinical outcome and diagnostic studies. Genetic samples are being examined in this cohort to determine whether certain to determine whether certain beta-AR polymorphisms as well as other common genetic polymorphisms are associated with different morphological features, such as LVH in patients with HCM and whether these polymorphisms influence the clinical course and outcome in patients with HCM. For that purpose, we will build a database with clinical information including serial echocardiographic measurements for patients with HCM that have regular follow up and test them for beta-AR polymorphisms as well as other common genetic polymorphisms and other known cardiac-related polymorphisms that can potentially contribute to the morphologic differences seen in patients with HCM.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertrophic Cardiomyopathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18+ years of age
* Diagnosed with HCM defined by the presence of left ventricular hypertrophy with minimal wall thickness \>/= 15mm without the presence of hypertension or systemic disease that can account for the degree of hypertrophy.

Exclusion Criteria

* Hypertension present prior to the diagnosis of HCM
* aortic stenosis with aortic valve area \< 1cm2
* known systemic disease that can cause LVH, such as infiltrative diseases
* able and willing to provide informed consent

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No